Oxurion Reports Results of THR-687 in Part A of P-II (INTEGRAL) Trial for the Treatment of Diabetic Macular Edema
Shots:
- The company reported the results from part A of the P-II (INTEGRAL) trial to evaluate THR-687 (1.2/2.0mg), administered in three monthly IVT inj. for treatment naïve patients with DME
- The trial failed to meet the efficacy EPs while the therapy was found to be safe and well-tolerated with no serious AEs and no patients required rescue medication @3mos. The company has decided to discontinue the development of THR-687 in Part B of (the INTEGRAL) trial, based on the part A results
- THR-687 is the integrin antagonist. Additionally, the company initiates the patients' enrolment in part B of the P-II (KALAHARI) trial for THR-149 in DME patients across the US & EU with an expected result in 2023
Ref: Globenewswire | Image: Oxurion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
